Literature DB >> 1972554

Glucagon secretion is essential for aminoacid-induced hyperfiltration in man.

G Friedlander1, F Blanchet-Benqué, A Nitenberg, C Laborie, R Assan, C Amiel.   

Abstract

The role of glucagon as a mediator of aminoacid-induced alteration of renal haemodynamics was evaluated in man in three different protocols. In the first it was shown that the increase in glomerular filtration rate (GFR) and renal plasma flow (RPF) observed during an aminoacid infusion was prevented by the additional infusion of somatostatin (SRIF), but reproduced by a glucagon infusion in the presence of SRIF. In the second protocol it was shown that, at variance with normal subjects, six totally pancreatectomised patients, thus deprived of pancreatic glucagon secretion, did not increase their GFR and RPF when infused with amino-acids, whereas they exhibited the expected hyperfiltration when infused with glucagon. In the third protocol it was shown that glucagon infusion in a renal artery did not alter the homolateral renal haemodynamics. It is concluded that glucagon secretion is a mandatory step in the cascade of events linking the infusion of aminoacids to the renal hyperfiltration. Other steps beyond glucagon secretion are necessarily involved because glucagon has no direct renal effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972554     DOI: 10.1093/ndt/5.2.110

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

1.  Cyclic AMP is a hepatorenal link influencing natriuresis and contributing to glucagon-induced hyperfiltration in rats.

Authors:  M Ahloulay; M Déchaux; C Hassler; N Bouby; L Bankir
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

2.  Differential Impact of Dietary Branched Chain and Aromatic Amino Acids on Chronic Kidney Disease Progression in Rats.

Authors:  Samyuktha Muralidharan Pillai; Brigitte Herzog; Petra Seebeck; Giovanni Pellegrini; Eva Roth; François Verrey
Journal:  Front Physiol       Date:  2019-12-09       Impact factor: 4.566

3.  Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.

Authors:  Victoria E R Parker; Thuong Hoang; Heike Schlichthaar; Fraser W Gibb; Barbara Wenzel; Maximillian G Posch; Ludger Rose; Yi-Ting Chang; Marcella Petrone; Lars Hansen; Philip Ambery; Lutz Jermutus; Hiddo J L Heerspink; Rory J McCrimmon
Journal:  Diabetes Obes Metab       Date:  2022-04-25       Impact factor: 6.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.